dc.creatorGomes, Renata N
dc.creatorColquhoun, Alison
dc.date.accessioned2013-11-04T14:23:13Z
dc.date.accessioned2018-07-04T16:11:52Z
dc.date.available2013-11-04T14:23:13Z
dc.date.available2018-07-04T16:11:52Z
dc.date.created2013-11-04T14:23:13Z
dc.date.issued2012
dc.identifierLIPIDS IN HEALTH AND DISEASE, v. 11, 2012
dc.identifier1476-511X
dc.identifierhttp://www.producao.usp.br/handle/BDPI/40814
dc.identifier10.1186/1476-511X-11-171
dc.identifierhttp://dx.doi.org/10.1186/1476-511X-11-171
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1632718
dc.description.abstractBackground: In many types of cancer, prostaglandin E-2 (PGE(2)) is associated with tumour related processes including proliferation, migration, angiogenesis and apoptosis. However in gliomas the role of this prostanoid is poorly understood. Here, we report on the proliferative, migratory, and apoptotic effects of PGE(1), PGE(2) and Ibuprofen (IBP) observed in the T98G human glioma cell line in vitro. Methods: T98G human glioma cells were treated with IBP, PGE(1) or PGE(2) at varying concentrations for 24-72 hours. Cell proliferation, mitotic index and apoptotic index were determined for each treatment. Caspase-9 and caspase-3 activity was measured using fluorescent probes in live cells (FITC-LEHD-FMK and FITC-DEVD-FMK respectively). The migratory capacity of the cells was quantified using a scratch migration assay and a transwell migration assay. Results: A significant decrease was seen in cell number (54%) in the presence of 50 mu M IBP. Mitotic index and bromodeoxyuridine (BrdU) incorporation were also decreased 57% and 65%, respectively, by IBP. The apoptotic index was increased (167%) and the in situ activity of caspase-9 and caspase-3 was evident in IBP treated cells. The inhibition of COX activity by IBP also caused a significant inhibition of cell migration in the monolayer scratch assay (74%) and the transwell migration assay (36%). In contrast, the presence of exogenous PGE(1) or PGE(2) caused significant increases in cell number (37% PGE(1) and 45% PGE(2)). When mitotic index was measured no change was found for either PG treatment. However, the BrdU incorporation rate was significantly increased by PGE(1) (62%) and to a greater extent by PGE(2) (100%). The apoptotic index was unchanged by exogenous PGs. The addition of exogenous PGs caused an increase in cell migration in the monolayer scratch assay (43% PGE(1) and 44% PGE(2)) and the transwell migration assay (28% PGE(1) and 68% PGE(2)). Conclusions: The present study demonstrated that treatments which alter PGE(1) and PGE(2) metabolism influence the proliferative and apoptotic indices of T98G glioma cells. The migratory capacity of the cells was also significantly affected by the change in prostaglandin metabolism. Modifying PG metabolism remains an interesting target for future studies in gliomas.
dc.languageeng
dc.publisherBIOMED CENTRAL LTD
dc.relationLIPIDS IN HEALTH AND DISEASE
dc.rightsCopyright BIOMED CENTRAL LTD
dc.rightsopenAccess
dc.subjectGLIOMA
dc.subjectPROSTAGLANDIN
dc.subjectIBUPROFEN
dc.subjectAPOPTOSIS
dc.subjectMIGRATION
dc.titleE series prostaglandins alter the proliferative, apoptotic and migratory properties of T98G human glioma cells in vitro
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución